Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 6/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812519 | 0.80 | RECQL (0.46) | GABRA2GABRB2BRD4KDM4EHSD17B10 | |
| SCHEMBL7921350 | 0.79 | KDM4E (0.50) | BRD4KDM4EHSD17B10NR1H2NR1H3 | |
| SCHEMBL27376921 | 0.79 | CYP1A2 (0.49) | GABRA2GABRB2BRD4KDM4ECYP1A2 | |
| SCHEMBL23505039 | 0.73 | GABRA2 (0.68) | GABRA2GABRB2CYP1A2NR1H2NR1H3 | |
| SCHEMBL4417830 | 0.72 | BRD4 (0.54) | GABRA2GABRB2BRD4KDM4EHSD17B10 | |
| SCHEMBL4812511 | 0.72 | NR4A2 (0.43) | GABRA2GABRB2BRD4KDM4EHSD17B10 | |
| SCHEMBL27602205 | 0.71 | BRD4 (0.50) | GABRA2GABRB2BRD4KDM4EHSD17B10 | |
| SCHEMBL14861721 | 0.69 | KDM4E (0.40) | GABRA2GABRB2KDM4ECYP1A2NR1H2 | |
| SCHEMBL19284340 | 0.69 | GABRA2 (0.46) | GABRA2GABRB2BRD4KDM4EHSD17B10 | |
| SCHEMBL4419725 | 0.69 | BRD4 (0.67) | GABRB2BRD4NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361665-B2 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-22 | — | — | US | disclosed |
| US-20040097531-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097531-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, AURKC, CDK5 | GABRA2 4824/4885GABRB2 4763/4885BRD4 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.